NASDAQ: MCRBSeres Therapeutics Inc Stock
$0.37-0.03 (-7.5%)
Updated Apr 17, 2025
MCRB Price
$0.37
Fair Value Price
-$0.39
Market Cap
$64.51M
52 Week Low
$0.36
52 Week High
$1.53
P/E
N/A
P/B
4.68x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
$136.00k
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
9.14
Operating Cash Flow
-$149M
Beta
1.32
Next Earnings
May 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
MCRB Overview
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MCRB's potential to beat the market
- MCRB doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MCRB
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important MCRB news, forecast changes, insider trades & much more!
MCRB News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MCRB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MCRB ($0.37) is overvalued by 194.5% relative to our estimate of its Fair Value price of -$0.39 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MCRB ($0.37) is not significantly undervalued (194.5%) relative to our estimate of its Fair Value price of -$0.39 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MCRB is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more MCRB due diligence checks available for Premium users.
Valuation
MCRB fair value
Fair Value of MCRB stock based on Discounted Cash Flow (DCF)
Price
$0.37
Fair Value
-$0.39
Undervalued by
194.50%
MCRB ($0.37) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MCRB ($0.37) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MCRB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
-177.72x
Market
27.98x
MCRB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.68x
Industry
4.05x
MCRB is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MCRB's financial health
Profit margin
Revenue
$0.0
Net Income
-$15.6M
Profit Margin
0%
MCRB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$139.8M
Liabilities
$126.0M
Debt to equity
9.14
MCRB's short-term liabilities ($41.22M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MCRB's long-term liabilities ($84.80M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MCRB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MCRB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$38.9M
Investing
-$90.0k
Financing
$1.7M
MCRB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MCRB vs Biotech Stocks
Seres Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.